This article has been disseminated on behalf of Optimi Health Corp. and may include paid advertising.
Optimi Health (NASDAQ: OPTH) (CSE: OPTI) (FSE: 8BN) announced the pricing of its underwritten public offering in connection with its uplisting to the Nasdaq Capital Market, offering 2.4 million common shares at US$6.25 per share for expected gross proceeds of approximately US$15 million, excluding any exercise of the underwriter’s option to purchase up to an additional 360,000 shares. Joseph Gunnar & Co. LLC is acting as sole book-running manager for the offering, with trading on Nasdaq expected to begin May 20, 2026, under the symbol OPTH.
The company said it intends to use net proceeds to scale production and distribution of its psychedelic drug products, support market expansion including into the United States, and fund sales growth, working capital and operating expenses. Optimi also confirmed the effectiveness of its previously announced 1-for-30 share consolidation, resulting in approximately 3.2 million common shares outstanding prior to the offering, subject to rounding and any additional issuances.
To view the full press release, visit https://ibn.fm/iwNJ5
About Optimi Health Corp.
Optimi Health Corp. (NASDAQ: OPTH) (CSE: OPTI) (FSE: 8BN) is a commercial-stage pharmaceutical company focused on manufacturing and distributing GMP-grade psychedelic drug products for mental health therapies. As a Health Canada-licensed pharmaceutical manufacturer, Optimi produces validated MDMA and botanical psilocybin drug products at its GMP-compliant facilities in British Columbia, Canada.
Optimi supplies both active pharmaceutical ingredients and finished dosage forms to regulated clinical and therapeutic programs internationally, with products currently prescribed to patients in Australia under the country’s Authorized Prescriber Scheme and accessible in Canada through the Special Access Program.
For more information, please visit https://www.optimi.net/
About InvestorWire
InvestorWire (“IW”) is a specialized communications platform with a focus on advanced wire-grade press release syndication for private and public companies and the investment community. It is one of 75+ brands within the Dynamic Brand Portfolio @ IBN that delivers: (1) access to a vast network of wire solutions via InvestorWire to efficiently and effectively reach a myriad of target markets, demographics and diverse industries; (2) article and editorial syndication to 5,000+ outlets; (3) enhanced press release enhancement to ensure maximum impact; (4) social media distribution via IBN to millions of social media followers; and (5) a full array of tailored corporate communications solutions. With broad reach and a seasoned team of contributing journalists and writers, IW is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists and the general public. By cutting through the overload of information in today’s market, IW brings its clients unparalleled recognition and brand awareness. IW is where breaking news, insightful content and actionable information converge.
For more information, please visit https://www.InvestorWire.com
Please see full terms of use and disclaimers on the InvestorWire website applicable to all content provided by IW, wherever published or re-published: https://www.InvestorWire.com/Disclaimer
InvestorWire
Austin, Texas
www.InvestorWire.com
512.354.7000 Office
[email protected]
InvestorWire is powered by IBN